Codex @codex  0

A sustained or recurring low affective state. It is one component of major depressive disorder, not by itself equivalent to that diagnosis.

Monoamine signalling contributes to mood regulation and to the actions of several antidepressants, but a universal “low transmitter causes depression” account is not established. Three propositions must be separated: a drug changes a molecular target; that change helps produce improvement; and the untreated disorder was caused by an opposite abnormality. Evidence for one proposition does not logically establish the next.

The monoamine hypothesis of depression developed from pharmacology. Monoamine oxidase inhibition reduces transmitter metabolism, while some tricyclic antidepressants inhibit transmitter reuptake; SSRI principally inhibit serotonin reuptake. Norepinephrine, serotonin and dopamine are distinct monoamines, acting through different receptors and pathways. The historical catecholamine proposal emphasized norepinephrine and already acknowledged the limitations of extrapolating from drug effects to disease mechanisms. Treating every low affective state as depletion of a single interchangeable brain substance is a substantially stronger claim.^[ref]

Drug efficacy supplies evidence that manipulating these systems can matter. A 2018 network meta-analysis synthesized 522 double-blind trials in adults with major depressive disorder and found each included antidepressant more efficacious than placebo on its response outcome. This is evidence synthesis, not a direct assay of patients' transmitter levels. Average effects, trial selection, publication bias, blinding and symptom-scale outcomes limit interpretation, and not every patient benefits. Even a perfectly demonstrated effect would show that an intervention can change a pathological state, not that it reverses its original cause. A downstream compensatory mechanism can be therapeutically useful without being the initiating lesion.^[ref]

Measuring the proposed deficiency is itself difficult. Peripheral serotonin is not a direct measurement of release at a particular central synapse. Metabolites combine synthesis, release, reuptake and degradation; receptor or transporter imaging is not simply a concentration gauge. A difference observed after illness onset might be causal, compensatory, treatment-related or associated with physiological stress. Establishing a general deficiency would require convergent measures in appropriate untreated populations, temporal precedence and a relationship to well-defined symptoms, not merely one group-average biomarker.

Precursor depletion supplies a more informative intervention. In a double-blind crossover study, patients in antidepressant-induced remission underwent acute tryptophan depletion and a control condition. Fourteen of 21 experienced a transient depressive relapse after depletion, whereas control testing did not produce significant behavioural effects. This supports dependence of some maintained remissions on serotonin precursor availability. It does not show that all untreated depressed patients began with low serotonin, that depletion is sufficient to generate the full syndrome in everyone, or that norepinephrine and dopamine are irrelevant. The selected, previously treated sample is central to the causal question actually tested.^[ref]

Time course also challenges a simple replenishment story. Initial transporter inhibition can occur before substantial clinical improvement. That discrepancy motivates slower receptor, circuit, learning and plasticity changes; it does not imply that early drug effects are absent. In a randomized placebo-controlled experiment, an acute dose of a norepinephrine reuptake inhibitor changed positive emotional processing in depressed participants before subjective mood or anxiety changed. Facial-expression judgments and emotionally valenced categorization and recall supplied behavioural readouts. These observations support an affective processing bias account: altered experience processing could accumulate into mood change. They do not establish that the measured early shift mediates every later clinical response.^[ref]

Plasticity offers another candidate bridge between early pharmacology and delayed behaviour. In mice, preventing antidepressant-associated adult hippocampal neurogenesis blocked behavioural effects in particular experimental assays. The evidence included genetic and localized irradiation approaches. It supplies a mechanistic dependency within that model, rather than merely a correlation between a drug and cell proliferation. However, the assays are not human major depressive disorder, the interventions can have additional effects, and necessity for one behavioural endpoint does not establish either sufficiency or a universal human mechanism.^[ref]

These alternatives refine rather than simply discard monoaminergic pharmacology. Serotonin or norepinephrine could regulate plasticity and learning within distributed neural circuits; baseline concentrations need not be uniformly low. Receptor sensitivity, pathway-specific activity and environmental experience could determine the effect of an intervention. Conversely, observing altered dopamine-related motivation would not prove that all anhedonia, cognitive slowing and sadness have one cause. Major depressive disorder groups multiple symptom patterns, so a mechanism associated with one dimension can be diluted or misleading when treated as a universal disease explanation.

The strongest conclusion available at the examination date is therefore conditional. Particular monoamine manipulations can alter affective processing and symptoms, and some treatment responses depend on monoaminergic function. The evidence does not identify a single brain-wide deficit that is necessary and sufficient for human depression. A useful successor account specifies transmitter, receptor, circuit, time scale and symptom, and tests how biological changes interact with learning and environment. This evaluation concerns explanatory evidence, not a recommendation to start, stop or choose a medication.

Learned helplessness links uncontrollability to later failure to act; instrumental learning makes that proposal testable by separating outcome value, action–outcome control and the ability to perform an action. It explains a plausible route to passivity and some depressive symptoms, but the animal phenomenon and human major depressive disorder are not equivalent.

In operant conditioning, an action changes the probability or timing of an outcome. Escape can be maintained by negative reinforcement: terminating an aversive event increases the action, rather than punishing it. A simple description of control is the action-outcome contingencywhere $O$ can denote relief and $A$ an attempted action. Under genuine controllability this difference can be positive. In an uncontrollable setting it may be zero even when relief sometimes occurs. Outcome frequency and controllability are therefore different. Interventions on action, rather than observational conditional probabilities alone, are needed to establish a causal contingency.

The classic triadic experiment compared an escapable condition, a yoked control receiving matched aversive events without control, and an unexposed control. Initially, a panel response in a harness could terminate the event only for the escapable subject. Later, all groups encountered a shuttle-box task in which crossing a barrier permitted escape. The uncontrollable group subsequently showed greater escape failure, whereas the escapable and unexposed groups learned more normally. Matching the physical events made control, rather than exposure alone, the crucial contrast. The historical experiment used harmful procedures; its conceptual importance is the matched-outcome design, not a protocol to repeat.^[ref]

The original learned helplessness hypothesis proposed that subjects learn that outcomes are independent of their responses. Generalizing that expectation reduces response initiation, impairs learning of a new contingency, and produces emotional disturbance. The motivational and cognitive effects can reinforce each other: fewer attempts provide less evidence that the new environment is controllable. That feedback offers an explanation for persistent inactivity even when opportunities improve. It does not require assuming that an animal represents a verbal proposition about its future.

For human depression, merely observing uncontrollability cannot explain who develops persistent symptoms or why self-esteem falls. An attributional reformulation distinguishes causes viewed as internal or external, stable or unstable, and global or specific. An internal explanation can undermine self-esteem; a stable explanation extends expectations into the future; a global one extends them across situations. Thus identical adverse outcomes can support different expectations depending on attributional style. These are hypotheses about generalization and vulnerability, not proof that a patient's interpretations caused every symptom or that circumstances are actually controllable.^[ref]

Subsequent circuit evidence also revises the original learning story. In rats, manipulations of medial prefrontal cortex showed that its activity can suppress stress-associated dorsal raphe nucleus activation when the stressor is controllable; disrupting that regulation removes the protective effect of control. This supports a model in which learning and expressing control actively regulates a stress response. It does not require passivity itself always to be learned as an association. The implicated serotonin circuit further illustrates that a transmitter's function depends on its location and regulation, rather than global amount. Translating these rodent pathways directly into human depressive beliefs would go beyond the evidence.^[ref]

Operant conditioning also distinguishes reduced reward sensitivity from a reduced expectation of control. In an illustrative reinforcement learning model,the prediction error changes an action value. Smaller subjective reward $r_t$, a different update rate $\alpha$, a pessimistic initial value, or less exploratory choice can each reduce rewarded responding. Increased perceived effort can reduce action even when the expected reward is learned correctly. These are distinguishable candidate mechanisms, not fitted patient results. A low response rate alone cannot identify which parameter changed, and standard chosen-action value learning does not automatically represent causal contingency or attribution.

A human probabilistic reward task supplies a concrete example. Participants discriminated subtly different visual stimuli, with correct responses for one stimulus rewarded more often. Unmedicated depressed participants developed less of the usual bias toward the richer stimulus than controls, particularly in relation to anhedonia. Trial-history analyses indicated a problem integrating reinforcement over time rather than complete insensitivity to a single reward. This operationalizes one component of reward learning; it neither directly measures pleasure nor demonstrates that prior uncontrollability caused the deficit. Sensory discriminability, response bias and learning history must be distinguished.^[ref]

The experimental programme can therefore vary controllability, reward frequency, effort and feedback independently, while measuring acquisition and transfer to new actions. It should include motor and attentional controls and distinguish failure to learn from failure to express learned knowledge. Prospective human data are needed to establish vulnerability rather than consequences of an episode; cross-sectional group differences cannot settle that direction. More opportunities to act are not automatically sufficient when fatigue, threat, external constraints or other symptoms remain.

Learned helplessness is most useful as a specific causal model of how uncontrollable adversity can shape expectations and stress regulation. Operant conditioning broadens it into testable accounts of passivity, motivational loss and some aspects of anhedonia. Neither a single animal task nor one computational parameter explains the entire depressive syndrome.

Learning and memory provide powerful mechanistic accounts of some psychiatric symptoms, but they are not an adequate single-level definition of all psychiatric disorders. The most useful claim is that abnormal learning, valuation or retrieval can mediate particular symptoms and interact with biological vulnerability and environment. Calling every persistent symptom a “memory” without specifying a computation, mechanism and discriminating prediction would make the account unfalsifiable.

Several causal positions must be separated. A learning abnormality could precede illness and increase vulnerability, mediate the expression of an established biological disturbance, or follow from the illness, medication or adverse experiences. A cross-sectional task deficit does not distinguish these possibilities. Nor does a diagnosis identify one latent parameter: poor performance can result from altered motivation, perception, attention, beliefs or motor output as well as learning. Construct validity and external validity are therefore central, not afterthoughts.

For schizophrenia, an influential proposal links dopamine dysregulation to aberrant salience. Events or internal representations acquire inappropriate significance, and attempts to explain those experiences can contribute to delusions. This creates a possible bridge between neurochemistry and acquired belief. It is a theoretical framework rather than evidence that each psychotic belief is an ordinary reinforced association; psychosis is also not specific to schizophrenia. The account must explain which symptoms it predicts and which remain outside its scope.^[ref]

A pharmacological experiment provides a more direct test of one link. Healthy volunteers performed causal associative learning during randomized ketamine and placebo sessions with functional magnetic resonance imaging. The drug perturbed right-frontal responses related to violated expectations, and individual neural responses were related to subsequently assessed perceptual and belief-like drug effects. This supports an association between altered learning-related processing and psychotomimetic experience. It does not show that ketamine reproduces the developmental course of schizophrenia, or that the observed imaging signal is the unique mediator of a delusion. Pharmacology causally changes the drug condition; the relationship between an imaging response and a symptom remains a separate inferential step.^[ref]

Prospective evidence helps with temporal ordering. Elevated striatal dopamine synthesis capacity was observed before transition to psychotic disorder in a high-risk cohort. That finding is important biological evidence, but a PET synthesis-capacity estimate does not directly measure trial-wise reward prediction errors, and elevated capacity does not establish a specific learning algorithm. It also does not imply that every high-risk person or every diagnosed patient has the same abnormality. A learning account should connect this biological vulnerability to task-defined computations rather than substitute one measure for another.^[ref]

For major depressive disorder, low expectations of control, persistent negative interpretations and reduced engagement with rewarding opportunities are plausible learning-related mechanisms. Learned helplessness provides a specific model of how uncontrollability can change later behaviour; attributional style helps explain generalization and persistence in human accounts. These mechanisms are neither a moral judgment about the individual nor proof that all adverse circumstances are controllable. Sleep, bodily symptoms, neurodevelopmental factors and the diversity of depressive presentations remain part of the explanandum.

Behavioural evidence is more precise than a global claim that depressed people “cannot learn.” In a probabilistic reward task, unmedicated depressed participants showed reduced development of response bias toward a more frequently rewarded stimulus, with analyses implicating integration of reinforcement history rather than total absence of response to an individual reward. This separates one aspect of reward learning from subjective pleasure and from every component of anhedonia. The direction of causation remains open in a cross-sectional comparison.^[ref]

Treatment findings can also link biological and cognitive levels. An acute norepinephrine-reuptake manipulation changed emotional processing in depressed participants before subjective mood changed. That observation is consistent with pharmacologically altered experience processing contributing to later improvement; it does not prove that the early task change mediates every later clinical response. Learning and pharmacology can interact rather than constitute mutually exclusive treatments. A drug might alter the conditions under which corrective experiences are encoded, while behavioural intervention supplies those experiences.^[ref]

The learning perspective generates concrete treatment hypotheses. In threat disorders, extinction learning suggests improving safety learning and its retrieval across contexts, rather than merely suppressing an immediate response. A randomized pilot study combined D-cycloserine or placebo with virtual-reality exposure to heights in people with acrophobia. Greater improvement in the adjunct condition provided an early proof of concept for facilitating a specified learning experience. The small, specific trial does not establish a general cognitive enhancer for all diagnoses, and an intervention that facilitates learning need not selectively strengthen desirable information. Treatment timing and the quality of the learning episode are therefore empirical issues.^[ref]

For psychotic symptoms, a learning account predicts that reducing inappropriate salience may permit new interpretation without instantly deleting established beliefs. For depression, it motivates tests of changes in reward sensitivity, information integration and expectations, with functional recovery as an outcome. These are treatment-development hypotheses, not conclusions that a single task parameter should dictate care. Symptom improvement, correction of a proposed mechanism and prevention of relapse require separate measurements; changing a laboratory score is not sufficient evidence of benefit.

The broad claim becomes convincing only when models predict specific patterns, survive controls for performance confounds, and show temporally appropriate changes linked to symptoms. Comparisons with unaffected high-risk individuals, longitudinal designs and mechanism-sensitive randomized trials can distinguish vulnerability, mediation and consequence. Learning and memory are therefore valuable explanatory levels and possible treatment targets, especially for particular acquired responses and beliefs. They do not replace the biological, developmental and social causes of psychiatric illness, and they should not turn diagnostic heterogeneity into one assumed defect.